Stone House Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Stone House Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.07K	Hold	1,000	–	–	﹤0.01%	524
2025 Q4	$4.09K	Hold	1,000	–	–	﹤0.01%	464
2025 Q3	$4.88K	Hold	1,000	–	–	﹤0.01%	374
2025 Q2	$5.06K	Sell	1,000 -200	-17%	-$983	﹤0.01%	323
2025 Q1	$6.35K	Buy	+1,200	New	+$8.75K	﹤0.01%	292
2024 Q4	–	Sell	-1,000	Closed	-$6.59K	–	289
2024 Q3	$6.59K	Hold	1,000	–	–	﹤0.01%	251
2024 Q2	$7.5K	Buy	1,000 +905	+953%	+$7.89K	﹤0.01%	246
2024 Q1	$947	Buy	+95	New	+$1.06K	﹤0.01%	386

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stone House Investment Management's RXRX Position: Q1 2026 in Review

Stone House Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 1,000 shares worth $3.07K. The position accounts for ﹤0.01% of the portfolio, ranked #524.

Stone House Investment Management first reported a position in RXRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.5K in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Stone House Investment Management held 1,000 shares of Recursion Pharmaceuticals worth $3.07K as of Q1 2026.
Stone House Investment Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #524 holding.
Stone House Investment Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Stone House Investment Management's Recursion Pharmaceuticals position peaked at $7.5K in Q2 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.